support@mellalta.com   +1 (304) 306-0723

Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017) Future Strategy & Latest Events

Liso-cel Strategy

Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover […]

Read More

Gene Research collaboration of Cabaletta Bio’s CABA Platform (CAART cell therapy) & Artisan Bio’s STARS Platform (Genome engineering)

Cabeletta-Bio-Artisian-Bio-CARRT-Cell-Therapy

Artisan bio entered into a gene editing research agreement with Cabaletta, which allows it to integrate Artisan’s advanced gene editing and engineering technology into Cabeletta’s next-generation CAAR T products as the company continues to expand […]

Read More

JNJ‑4528-Investigation Treatment for R/R Multiple Myeloma, has it all (Breakthrough Designation, Effective Results & Excited KOLs)

JNJ‑4528

Legend Biotech Corporation, announced the updated results from the Janssen sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528) in multiple myeloma. There is something interesting about the drug, JNJ-4528 […]

Read More

Adoptive TCR Therapy -A Revolution in Immuno-oncology Therapeutic Modality

Adoptive T-cell therapy is one potentially groundbreaking treatment for cancer that genetically alters natural T cells to make them tumor-specific and to improve their ability to destroy tumor cells. The genetically modified T cells are able to express chimeric […]

Read More

Get In Touch

Let's keep the conversation going